Clinical trials in Nieuwegein – page 11

161 clinical trials in Nieuwegein, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Nieuwegein at a glance

161

clinical trials

Research sites2

Quick filters

161 trials in Nieuwegein

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Breast cancer stage III+2

Not recruiting

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Colorectal cancer+1

Not recruiting

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Catharina Ziekenhuis Stichting

Contact Research Centre

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Brentuximab Vedotin
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Pulmonary hypertension+1

Not recruiting

Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

Registered drugNo placebo

Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Acenocoumarol
Sponsor:St Antonius Hospital

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effectiveness and Safety of LTP001 for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Study on the Effectiveness and Safety of LTP001 for Patients with Idiopathic Pulmonary Fibrosis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ltp001
Sponsor:Novartis Pharma AG

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bexotegrast
Sponsor:Pliant Therapeutics Inc.

Contact Research Centre

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Nieuwegein

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on idiopathic pulmonary fibrosis and related conditions, evaluating new therapeutic approaches for lung diseases. Studies include assessment of novel treatments for systemic autoimmune rheumatic diseases with lung involvement.

Pulmonary Fibrosis Treatment
Interstitial Lung Disease
Rheumatic Disease-Related Lung Conditions

Multiple trials are investigating both targeted therapies and comprehensive treatment approaches.

02 Oncology Research

Comprehensive studies in cancer treatment, particularly focusing on prostate cancer and urothelial cancer. Advanced imaging techniques and novel therapeutic combinations are being evaluated for improved patient outcomes.

Advanced Colorectal Cancer
Acute Myeloid Leukemia
Bladder Cancer Therapeutics

Trials are exploring personalized treatment approaches and innovative drug combinations.

03 Neurological Disorders

Research initiatives addressing status epilepticus and post-cardiac arrest care. Studies include innovative approaches for treating dementia and related behavioral issues.

Post-Cardiac Arrest Care
Dementia Management
Stroke Prevention

Investigations focus on both acute neurological conditions and long-term management strategies.

Back to the Netherlands All countries